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Huntington’s disease (HD) is a CAG repeat disorder affecting the HD gene, which encodes for huntingtin
(Htt) and is characterized by prominent cell death in the striatum. Oxidative stress was previously
implicated in HD neurodegeneration, but the role of the major endogenous antioxidant system, the
glutathione redox cycle, has been less studied following expression of full-length mutant Htt (FL-mHtt).
Thus, in this work we analyzed the glutathione system in striatal cells derived from HD knock-in mice
expressing mutant Htt versus wild-type cells. Mutant cells showed increased intracellular reactive
oxygen species (ROS) and caspase-3 activity, which were significantly prevented following treatment
with glutathione ethyl ester. Interestingly, mutant cells exhibited an increase in intracellular levels of
both reduced and oxidized forms of glutathione, and enhanced activities of glutathione peroxidase
(GPx) and glutathione reductase (GRed). Furthermore, glutathione-S-transferase (GST) and g-glutamyl
transpeptidase (g–GT) activities were also increased in mutant cells. Nevertheless, glutamate-cysteine
ligase (GCL) and glutathione synthetase (GS) activities and levels of GCL catalytic subunit were
decreased in cells expressing FL-mHtt, highly suggesting decreased de novo synthesis of glutathione.
Enhanced intracellular total glutathione, despite decreased synthesis, could be explained by decreased
extracellular glutathione in mutant cells. This occurred concomitantly with decreased mRNA expres-
sion levels and activity of the multidrug resistance protein 1 (Mrp1), a transport protein that mediates
cellular export of glutathione disulfide and glutathione conjugates. Additionally, inhibition of Mrp1
enhanced intracellular GSH in wild-type cells only. These data suggest that FL-mHtt affects the export
of glutathione by decreasing the expression of Mrp1. Data further suggest that boosting of GSH-related
antioxidant defense mechanisms induced by FL-mHtt is insufficient to counterbalance increased ROS
formation and emergent apoptotic features in HD striatal cells.
& 2012 Elsevier Inc. All rights reserved.Introduction
Huntington’s disease (HD) is the most prevalent polygluta-
mine expansion disorder, characterized by motor and psychiatric
disturbances and cognitive decline leading to dementia. HD is
inherited in an autosomal dominant manner and fatal 15 to 20
years after the symptoms onset, which occur around the fourth
decade of life in the majority of the patients [1]. The disease is
caused by a CAG triplet expansion in exon 1 of the HD gene,
leading to an increase in the size of the polyglutamine tail at the
N-terminal of the huntingtin (Htt) protein [2]. Expression of
mutant Htt (mHtt) causes striatal neurodegeneration and also
affects the cerebral cortex later in the course of the disease [3].ll rights reserved.
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c.pt,Oxidative stress is one of several dysfunctional mechanisms
described in HD [4–8], which may result from impaired mito-
chondrial function, namely due to interaction of the organelle
with mHtt [9] and/or imbalanced levels of antioxidants.
Altered oxidative parameters have been observed in both
central and peripheral samples of HD patients and in some animal
models of the disease. In HD postmortem tissues, levels of
8-hydroxydeoxyguanosine (8-OH-dG), a DNA oxidative damage
marker, and malondialdehyde (MDA), a lipid peroxidation mar-
ker, were increased in caudate nucleus and parietal cortex [4,10].
In HD patients’ blood plasma, elevated levels of 8-OH-dG were
observed [8,11]. Also, increased levels of 8-OH-dG [8] and MDA
[6] were previously observed, respectively, in leukocytes and
serum of HD patients. Concordantly, in R6/2 HD mice (expressing
exon 1 of the human HD gene), 8-OH-dG levels were shown to be
increased in striatum, urine, and plasma [12].
The levels of antioxidants also vary depending on the type of
tissue and possibly the stage of HD pathology. In striatum and
cortex of HD postmortem samples a proteomic analysis revealed
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glutathione peroxidase (GPx) 1 and 6, and an increase in super-
oxide dismutase (SOD)2 (Mn-SOD) and catalase activities, when
compared to control individuals [13]. Furthermore, increases in
mRNA levels of GPx1, catalase, and SOD1 (Cu/Zn-SOD) were
observed in striatal cells expressing full-length mHtt (FL-mHtt)
[14]; however, these studies did not analyze the enzymatic
activities of the antioxidant systems. Conversely, in erythrocytes
from HD patients, GPx and SOD1 activities were found to be
decreased, compared to unaffected subjects [8], suggesting an
impairment of the antioxidant defenses in HD peripheral samples.
Concordantly with increased levels of antioxidant proteins in
HD human brain, a significant increase in the levels of the reduced
form of glutathione (GSH) was observed in striatum of 8- to 12-
week-old R6/2 HD mice [15]. Enhanced GSH levels were also
detected in isolated mitochondria from both cortex and striatum
of R6/2 HD mice; however, glutamate-cysteine ligase (GCL), an
enzyme involved in the synthesis of GSH, was reported to be
actively decreased in both striatum and cortex of R6/2 HD mice,
not explaining the increase in GSH levels [16]. Moreover, in the
same study, glucose-6-phosphate dehydrogenase (G6PD) activity,
an enzyme that produces NADPH essential for glutathione reduc-
tase (GRed) activity, was also reported to be decreased in the
striatum of R6/2 HD mice [16]. Together, these observations show
some discrepancies in the antioxidant redox systems in HD,
namely associated with the glutathione redox cycle, evidencing
the need to clarify the regulation of antioxidant levels in striatal
cells expressing FL-mHtt. Thus, in this study, we detailed the
changes in the GSH antioxidant system in striatal cells derived
from HD knock-in mice. Our results indicate that expression of
FL-mHtt is accompanied by a heightening of GSH-related anti-
oxidant levels and activity due to reduced expression and
functional activity of multidrug resistance protein 1 (Mrp1).
Nevertheless, increased antioxidant activity appears to be insuffi-
cient, as HD cells exhibit increased reactive oxygen species (ROS)
generation and cell death features.Materials and methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum
(FBS), penicillin/streptomycin, and geneticin were purchased by
GIBCO (Paisley, UK). ATP, DL-dithiothreitol (DTT), NEM (N-ethylma-
leimide), NDA (2,3-naphthalenedicarboxaldehyde), maleimide,
g-Glu-Cys, L-glutamic acid, L-glutamine, OPA (o-phthaldialdehyde),
PMSF (phenylmethanesulfonyl fluoride), protease inhibitors (chy-
mostatin, pepstatin, A, leupeptin, and antipain), glucose-6-
phosphate, g-glutamylcysteine (g–GC), reduced glutathione (GSH),
oxidized glutathione or glutathione disulfide (GSSG), glutathione
reductase, NADP, NADPH, tert-butyl hydroperoxide, glutathione
reduced ethyl ester (GSHee), glutathione-S-transferase (GST) assay
kit, glycylglycine, 5-sulfosalicylic acid dihydrate, calcein-AM,
5-(3-(2-(7-chloroquinolin-2-yl)ethenyl)phenyl)-8-dimethylcarbamyl-
4,6-dithiaoctanoic acid (MK-571) sodium salt, and anti-b-actin were
from Sigma Chemical Co. (St. Louis, MO, USA). Anti-glutathione
reductase (GRed) and anti-glutamate-cysteine ligase catalytic (GCLc)
subunits were from Abcam (Cambridge, UK). Enhanced ChemiFluor-
escence reagent (ECF), anti-rabbit IgG (from goat), and anti-mouse
IgGþ IgM (from goat) were from GE Healthcare (Little Chalfort, UK).
The fluorescence probe 20,70-dichlorodihydrofluorescein diacetate
(H2DCFDA) and Trizol reagent were obtained from Molecular
Probes/Invitrogen (Eugene, OR, USA). Ac-DEVD-AFC was obtained
from Calbiochem/Merck Chemicals (Darmstadt, Germany). g-Gluta-
myl-7-amino-4-methyl-coumarin (g-glutamyl-AMC) was purchasedfrom Bachem (Bubendorf, Switzerland). First Strand cDNA Synthesis
Kit (AMV) was purchased from Roche (Mannheim, Germany). GoTaq
Flexi DNA polymerase (5x kit) and dNTP Mix were from Promega
(Madison, WI, USA).
Cell culture
Striatal cells expressing wild-type Htt (STHdhQ7/Q7 or wild-
type cells; clone 2aA5) or homozygous mutant cells derived
from knock-in mice, expressing FL-mHtt with 111 glutamines
(STHdhQ111/Q111cells; clone 109-1A), were kindly donated by
Dr. Marcy E. MacDonald (Department of Neurology, Massachu-
setts General Hospital, Boston, MA, USA). Cells were maintained
in an incubation chamber at 33 1C with 5% CO2, in DMEM culture
medium supplemented with 10% FBS, 2 mM glutamine, 1%
penicillin/streptomycin, and 400 mg/ml geneticin (G-418), as
described previously [17]. Striatal cells were plated on multiwell
chambers or flasks at a density of 0.06106 cells/cm2 48 h before
the experiments in order to allow the desired confluence. In some
experiments, cells were incubated with GSH ethyl ester (GSHee,
at 0.05, 0.25, or 1 mM) or 50 mM MK-571, for 24 h.
Preparation of mitochondrial-enriched fractions
Striatal cells were washed twice in PBS, lysed, and scraped
(4 1C) in a sucrose buffer (in mM: 250 sucrose, 20 Hepes/KOH
(pH 7.5), 100 KCl, 1.5 MgCl2, 1 EGTA, and 1 EDTA) supplemented
with 1 mM DTT, 100 mM PMSF, and 1 mg/ml protease inhibitors
(chymostatin, pepstatin A, leupeptin, and antipain). Cell lysates
were then homogenized with a potter (120 strokes) and centri-
fuged at 560 g for 12 min at 4 1C. The pellet (nuclei and cell debris)
was discarded and the supernatant was centrifuged at 12,000 g for
20 min at 4 1C to obtain a mitochondrial-enriched pellet. The
mitochondrial fraction was further resuspended in a supplemen-
ted sucrose buffer, and protein levels were determined using the
Bio-Rad protein assay (Bradford method). The mitochondrial-
enriched fractions were used for analysis of glutathione reduced
and oxidized form levels, and GRed, GPx, and GST activities.
Intracellular ROS measurements
After brief washing with PBS, striatal cells were incubated
for 30 min with 20 mM H2DCFDA, a stable nonfluorescent cell-
permeable compound, at 33 1C, in modified Krebs medium
(in mM: 135 NaCl, 5 KCl, 0.4 KH2PO4, 1.8 CaCl2, 1 MgSO4,
20 Hepes, and 5.5 glucose) at pH 7.4. H2DCFDA is incorporated
by the cells and hydrolyzed by esterases to form H2DCF, which is
converted to DCF by intracellular peroxides [18]. Intracellular levels
of peroxides were measured by following DCF fluorescence
(488 nm excitation, 530 nm emission) at 33 1C, continuously, for
1 h, using a Gemini EM microplate spectrofluorometer (Molecular
Devices, USA). In order to correct the DCF fluorescence, values for
variations in total intracellular protein content in each well were
quantified by the Bio-Rad protein assay (Bradford method). The
values were obtained as RFU (relative fluorescence units) per
minute per milligram protein for each condition and then expressed
as percentage of wild-type cells.
Measurement of caspase-3 activity
Caspase-3 activity was determined using a fluorimetric sub-
strate Ac-DEVD-AFC. The DEVD sequence is cleaved by caspase-3
releasing the fluorogenic AFC which is quantified by fluorimetry.
Striatal cells were washed twice with PBS and then lysed at 4 1C
with a lysis buffer composed of (in mM): 25 Hepes, 2 MgCl2,
1 EDTA, 1 EGTA, supplemented with 1 mM DTT, 100 mM PMSF,
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and antipain) and 0.04% Triton X-100 (pH 7.5). After scraping,
a reaction buffer composed of 25 mM Hepes, 10% sucrose, 0.1%
Chaps, 2 mM DTT, and 15 mM Ac-DEVD-AFC (pH 7.5) was added
to the cell samples. The fluorescence was monitored for 1 h at
33 1C with excitation at 400 nm and emission at 505 nm. After the
readings, the samples were used to determine the amount of
protein per well. The values were obtained as RFU per minute per
milligram protein for each condition and then expressed as
percentage of wild-type cells.
Measurement of glutathione levels by fluorimetry
The cells were washed twice in PBS and lysed in 15 mM Tris,
pH 7.4, and the intracellular levels of reduced and oxidized
glutathione (GSH and GSSG, respectively) were determined using
a fluorimetric assay, according to a previously described method
[19]. GSH levels were measured in samples after the addition of
ortho-phthaldialdehyde (1 mg OPA/ml methanol) and 100 mM
NaH2PO4. After 15 min incubation, the fluorescence was mea-
sured using an excitation wavelength of 350 nm and an emission
wavelength of 420 nm. The experimental procedure for GSSG
was similar, although the samples were mixed for 30 min with
N-ethylmaleimide (5 mg NEM/ml methanol) which forms adducts
with GSH. Then, the mixture was incubated for 15 min in 100 mM
NaOH plus OPA (1 mg OPA/ml methanol), and the fluorescence
was measured with excitation at 350 nm and emission at 420 nm
in a Gemini EM microplate spectrofluorometer (Molecular
Devices, USA). The results were calculated as RFU per milligram
protein and expressed as percentage of wild-type cells or as
a percentage of control (untreated) conditions in the case of
MK-571 incubation.
Measurement of GPx and GRed activities
The cells were washed twice in PBS and lysed in 25 mM
Tris–HCl (pH 7.4) and then centrifuged at 20,800 g for 10 min,
at 4 1C (Eppendorf Centrifuge 5417R). The supernatant was used
for protein quantification using the Bio-Rad protein assay
(Bradford method) and for measuring GRed and GPx activities,
spectrophotometrically, at 340 nm, through the analysis of
NADPH oxidation, as described previously [20] with some mod-
ifications. Briefly, the activity of GPx in samples was measured on
a 5 min incubation, in the dark, with phosphate buffer containing
0.25 M KH2PO4, 0.25 M K2HPO4, and 0.5 mM EDTA, pH 7.0, 10 mM
GSH, and GRed (1 unit). The reaction occurred after the addition
of 2.5 mM NADPH and 12 mM tert-butyl hydroperoxide. For the
activity of GRed, each sample was incubated with a phosphate
buffer containing 0.2 M K2HPO4 and 2 mM EDTA, pH 7.0, plus
2 mM NADPH. The measurements were initiated with the addi-
tion of 20 mM GSSG. GRed and GPx activities were determined
using a SpectraMax Plus384 microplate spectrophotometer (Mole-
cular Devices, USA). Results were calculated as milliunits (mU)
per milligram protein and expressed as percentage of wild-type
cells.
Measurement of G6PD and 6PGD activities
Glucose-6-phosphate dehydrogenase (G6PD) activity was
determined according to Choo and collaborators [16], with some
minor modifications. Briefly, the cells were washed twice in PBS
and lysed in 25 mM Tris–HCl (pH 7.4) and then centrifuged
at 20,800g for 10 min, at 4 1C (Eppendorf Centrifuge 5417R). The
supernatant was used for protein quantification using the Bio-Rad
protein assay (Bradford method) and cell samples (30 mg) were
mixed with a reaction buffer containing (in mM): 0.38 NADP,6.3 MgCl2, 3.3 glucose-6-phosphate, and 5 maleimide (an inhi-
bitor of 6-phosphogluconate dehydrogenase (6PGD) activity) in
50 mM Tris–HCl (pH 7.5). For 6PGD activity determination,
experiments were performed in the absence of maleimide, corre-
sponding, therefore, to the total NADPH production (G6PDþ
6PGD) by the pentose phosphate pathway; thus 6PGD activity
¼ total NADPH production – G6PD activity. The NADPH produc-
tion was continuously monitored at 340 nm using a SpectraMax
Plus384 microplate spectrophotometer (Molecular Devices, USA)
at 37 1C and the results were calculated as milliunits (mU) per
milligram protein and expressed as percentage of wild-type cells.
Determination of GCL and GS activities
GCL and glutathione synthetase (GS) activities were measured
according to White and collaborators [21], with some minor
modifications [22]. Cells were washed twice with PBS and lysed
with 25 mM Tris–HCl (pH 7.4) plus 0.1 mM EDTA. Cellular
extracts were centrifuged at 20,800g for 10 min at 4 1C, and
protein content was analyzed by the Bio-Rad protein assay
(Bradford method). For GCL activity, 50 ml of sample was added
to 50 ml of GCL reaction buffer containing (in mM): 100 Tris,
10 ATP, 20 L-glutamic acid, 2 EDTA, 20 sodium borate, 2 serine,
and 40 MgCl2, and incubated at 37 1C for 5 min. The GCL reaction
was initiated by adding 50 ml of 2 mM L-cysteine. For GS activity,
L-glutamic acid and L-cysteine were replaced with 30 mM glycine
and 3 mM g-glutamylcysteine (g-GC), respectively. After 20 min
incubation, the GCL and GS reactions were stopped by adding
50 ml of 200 mM 5-sulfosalicylic acid. Samples were vortexed,
incubated on ice for 20 min, and centrifuged at 660 g at 4 1C, for
5 min. Then, 20 ml of supernatant was transferred into a 96-well
plate and 180 ml of 2,3-naphthalenedicarboxaldehyde (NDA)
derivatization solution (50 mM Tris, pH 10, 0.5 M NaOH, and
10 mM NDA in DMSO, v/v/v 1.4/0.2/0.2, respectively) was then
added to each well to form NDA-g-GC or NDA-GSH fluorescent
complexes. The fluorescence was detected at 472 nm excitation
and 528 nm emission, using a Gemini EM microplate spectro-
fluorometer (Molecular Devices, USA). The results were calculated
as RFU per milligram protein and expressed as percentage of
wild-type cells.
Measurement of glutathione-S-transferase activity
Determination of GST activity was performed accordingly to
the manual provided by the GST assay kit (Sigma). Briefly, after a
washing step in PBS, cell samples were mixed in a 96-well plate
with a substrate solution containing 1-chloro-2,4-dinitrobenzene
(CDNB) and GSH and the absorbance was followed at 340 nm for
6 min. The results were calculated in micromoles per minute per
milligram protein and expressed as percentage of wild-type cells.
Measurement of g-glutamyl transpeptidase activity
The cells were lysed at 4 1C in 100 mM Tris–HCl, 1 mM EDTA,
and 0.1% Triton X-100; pH 7.6; and g-glutamyl transpeptidase
(g–GT) activity was measured according to Zhu and collaborators
[22] with some modifications. Briefly, 50 ml of cell samples was
added to 50 ml of a reaction mixture containing 100 mM Tris–HCl
(pH 7.6), 40 mM glycylglycine, 40 mM g-glutamyl-7-amino-
4-methyl-coumarin (g-glutamyl-AMC), and 0.1% (v/v) Triton
X-100, in a 96-well plate. The fluorescence was measured with
excitation at 370 nm and emission at 440 nm, for 45 min at 33 1C.
The values were obtained as RFU per minute per milligram
protein for each condition and then expressed as percentage of
wild-type cells.
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HPLC
Extracellular cultured medium was collected, whereas the cells
were washed with PBS and further lysed in 1 M NaOH for
determination of intra- and extracellular levels of total glutathione
(GSHþGSSG). Both fractions were centrifuged at 20,800g, at 4 1C
for 10 min, to remove cell debris, and the supernatants were used
for total glutathione analysis in a Gilson-ASTED HPLC system.
Samples were separated on a Hichrom ACE-type column (150 
4.6 mm, 5 mM C18) at a flow rate of 2.5 ml/min for 45 min, using a
ternary solvent system consisting of solvent A [37.5 mM sodium
phosphate, 50 mM propionic acid, 7% acetonitrile, and 3% dimethyl
sulfoxide (pH 6.2)], solvent B (40% acetonitrile, 33% methanol, and
7% dimethyl sulfoxide), and solvent C [62.5 mM sodium phosphate,
50 mM propionic acid, 7% acetonitrile, and 3% dimethyl sulfoxide
(pH 5.5)]. Total glutathione was detected as a fluorescent deriva-
tive after precolumn derivatization with o-phthaldialdehyde/
2-mercaptoethanol (OPA/MCE), using a Gilson Model 121 fluorescent
detector, with excitation at 340 nm and emission at 410 nm. Total
glutathione levels were determined by comparison with peak areas
of GSH standards, calculated in nanomoles per milligram protein and
expressed as a percentage of wild-type cells. Protein levels were
determined by the Bio-Rad protein assay (Bradford method).
Analysis of Mrp1 activity based on calcein fluorescence
Mrp1 activity was determined based on calcein fluorescence,
since Mrp1 is involved in the transport of calcein to the extra-
cellular space [23]. Striatal cells were cultured for 24 h and then
briefly washed in PBS. After the washing step, the cells were
incubated with 5 mM calcein-AM in modified Krebs medium for
1 h, at 33 1C. Calcein-AM diffuses into cells where it is cleaved by
intracellular esterases, resulting in fluorescent calcein. After incu-
bation, striatal cells were washed twice in PBS and intracellular
calcein fluorescence was analyzed using excitation at 494 nm and
emission at 517 nm. The results were calculated as RFU per
milligram protein and expressed as a percentage of wild-type cells.
Western blotting
Striatal cells were washed twice in PBS and extracted in lysis
buffer containing (in mM): 20 Tris–HCl (pH 7), 100 NaCl, 2 EDTA,
2 EGTA, supplemented with 0.1 mM PMSF, 1% Triton X-100 and
1 mg/ml protease inhibitors (antipain, chymostatin, leupeptin, and
pepstatin A). Total extracts were centrifuged at 20,800g for 10
min in order to discard debris, and protein content was deter-
mined by the Bio-Rad protein assay (Bradford method). Samples
were denatured in 50 mM Tris–HCl, pH 6.8, containing 2% sodium
dodecyl sulfate (SDS), 5% glycerol, 0.01% bromophenol blue, and
100 mM DTT at 95 1C, for 5 min. Thirty micrograms of protein was
separated on a 12% SDS-PAGE and electroblotted onto polyviny-
lidene difluoride (PVDF) membranes. The membranes were
further blocked with 5% fat-free milk and incubated overnight
with anti-GRed (1:2000), anti-GCL (1:1000), or anti-b-actin
(1:10,000), used as loading control. Immunoreactive bands were
developed with ECF reagent, which is converted into a fluorescent
compound by alkaline phosphatase associated with the secondary
antibodies, and visualized using a Bio-Rad Versa Doc 3000
Imaging System.
Total RNA extraction and reverse transcriptase
RNA from different samples was obtained with Trizol reagent
according to the manufacturer’s protocol. Briefly, striatal cells were
lysed and homogenized with Trizol. The RNA was precipitated withisopropyl alcohol and the final pellet was resuspended with water
DEPC (diethylpyrocarbonate) at 0.01% (v/v). Before performing
reverse-transcriptase PCR (RT-PCR), the quality of RNA was verified
through an electrophoresis in 1% agarose gel to check the riboso-
mal RNA subunits 18S and 28S. Then, the samples were incubated
at 65 1C for 15 min, to avoid extensive secondary structure that
may interfere with the annealing step and then were chilled on ice
for 5 min. The concentration of RNA was measured and 1 mg was
used in each reaction to obtain the cDNA. RNA was transcribed into
cDNA in a template–primer mix using the First Strand cDNA
Synthesis Kit (AMV) (Roche, Mannheim, Germany). The reaction
was as follows: þ25 1C for 10 min and þ42 1C for 60 min, for
primer annealing and cDNA synthesis, respectively, þ99 1C for
5 min, for the denaturation of reverse transcriptase, and then the
samples were cooled to þ4 1C for 5 min.
Quantification of mRNA levels of G6PD and Mrp1
The concentration of the resulting single-stranded cDNA was
determined, and 10 ng was used to perform PCR to G6PD and
Mrp1. The cDNA of each sample was amplified using sequence-
specific primers to G6PD, forward (50–30) ATG GCA GAG CAG GTG
GCC, reverse (50–30) GCA CTG TTG GTG GAA GAT G; and to Mrp1,
forward (50–30) CTG CAC AAC CTG CGC TTC, reverse (50–30) GGT
GCC AGA GGC CAG AC. The normalization of the amplified
product was performed in relation to the product of actin
obtained in the same samples using as primers (50–30) GGA GAC
GGG GTC ACC CAC AC and (50–30) AGC CTC AGG GCA TCG GAA CC,
forward and reverse, respectively. All the reactions were per-
formed using GoTaq Flexi DNA polymerase (5x kit) and dNTP mix
10 mM. The amplification reaction mixture (50 ml) contained
10 ml of the cDNA template, 1.5 mM MgCl2, 0.2 mM of each
primer, 0.05 U Taq polymerase. The thermal cycling conditions
were 3 min at 94 1C, proceeding with 40 cycles of 94 1C for 30 s,
57 1C for 30 s, and 72 1C for 45 s, followed by 72 1C for 10 min. The
PCR products were visualized in 1.7% agarose gel and afterward
analyzed using a Bio-Rad Gel Doc 3000 Imaging System. The
results were presented as mRNA G6PD levels in relation to actin.
Statistical analysis
Statistical significance was determined by Student’s t test for
comparison between two Gaussian populations, or by two-way
ANOVA followed by the Bonferroni post test for analysis of multi-
ple groups, as described in the figure legends. Data were expressed
as the mean7SEM of the number of experiments indicated in the
figure legends. Significance was accepted at Po0.05.Results
ROS production and caspase-3 activation in HD striatal mutant
cells—influence of GSHee
In order to investigate ROS production in HD striatal cells derived
from knock-in mice, we used the fluorescent probe H2DCFDA which
has been reported to measure hydroperoxides, including H2O2,
ONOO–, and hypochlorous acid (HOCl) in viable cells [18,24].
A significant increase in ROS formation was observed in mutant
cells when compared to wild-type cells (Fig. 1A). Treatment with
GSHee, a cell-permeable ester of GSH (0.05, 0.25, and 1mM),
significantly decreased ROS levels in mutant cells to similar values
of wild-type (control) cells (Fig. 1A). Moreover, an increase in
caspase-3 activity was observed in mutant cells (Fig. 1B), which
might be related to the increase in ROS formation, as described
previously by us [1]. GSHee treatment also decreased caspase-3
Fig. 1. Effect of glutathione ethyl ester on ROS generation and caspase-3 activity in HD knock-in striatal cells. ROS formation and caspase-3 activity were measured in
wild-type and mutant cells before and after incubation with 0.05, 0.25, or 1 mM glutathione ethyl ester (GSHee) for 24h. (A) DCF fluorescence shows that mutant cells
produce significantly more peroxides than wild-type cells (696.6754.9 RFU/min/mg protein); GSHee supplementation significantly reduced ROS formation in mutant
cells, when compared to nontreated conditions. (B) Caspase-3 activity is increased in mutant cells and 0.25 mM GSHee protected against caspase-3 activation (caspase-3
activity in untreated wild-type cells: 404.1719.2 RFU/min/mg protein). Data are presented as mean7SEM of 3 to 5 independent experiments performed in duplicates,
triplicates, or 6 replicates. Statistical analysis was performed by two-way ANOVA followed by the Bonferroni post test for analysis of multiple groups: nnnPo0.0001 when
compared to wild-type cells; #Po0.05 and ###Po0.0001 when compared to nontreated conditions.
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GSHee. These results suggested that intracellular levels of the
reduced form of glutathione (GSH) might be insufficient to deal with
ROS produced in cells expressing mHtt. Thus, in the following
experiments we determined the changes in components of the
glutathione redox cycle in HD striatal cells.
Glutathione redox cycle Is affected on expression of
mutant huntingtin
GSH has been shown to be essential to detoxify cells against H2O2.
In order to investigate the levels of the glutathione antioxidant
defense systems present in striatal mutant and wild-type cells, we
measured the intracellular levels of GSH and GSSG. Surprisingly, a
significant increase in the levels of GSH (Fig. 2A and B) and GSSG
(Fig. 2C and D) was found in total (cellular) and mitochondrial
fractions of mutant cells, compared to wild-type cells. Taking into
account that both metabolites increased, the GSH/GSSG ratio was not
significantly changed in mutant versus wild-type cells, in both
cellular (GSH/GSSG ratio in wild-type cells: 7.4272.3) andmitochon-
drial (GSH/GSSG ratio in wild-type mitochondria: 6.272.1) fractions.
An increased intracellular pool of both GSH and GSSG suggested
an alteration of the glutathione redox cycle enzymes in HD knock-
in striatal cells. Thus, we further determined GPx and GRed
activities. GPx converts GSH and H2O2 into GSSG and H2O, respec-
tively. GRed uses GSSG and NADPH to produce GSH and NADPþ .
Concomitant with the alterations in GSH and GSSG, we observed a
significant increase in total and mitochondrial GPx activity in
mutant cells, when compared to wild-type cells (Fig. 2E and F).
Moreover, we observed that total and mitochondrial GRed activities
were increased in mutant cells, as compared to wild-type cells
(Fig. 2G and H). Altered GRed activity was not accounted for by
differences in protein expression levels between mutant and wild-
type cells, as determined by Western blotting (supplementary
Fig. S1). Analysis of GPx protein levels by Western blotting was
unsuccessful using two different antibodies to GPx-1.
NADPH and pentose-phosphate NADPH-producing enzymes are
increased in mutant cells
In order to explain the increase in activity of GRed in mutant
cells we further measured the activities of the pentose phosphatepathway enzymes, which are mainly responsible for producing
the NADPH necessary for GRed activity, namely G6PD and 6PGD.
Our results showed significant increases in G6PD and in 6PGD
activities in HD mutant cells, compared to wild-type cells (Fig. 3A
and B), corroborating our previous findings. However, no changes
in mRNA levels of G6PD were found in striatal cells (Fig. 3C).
Moreover, we observed significantly higher levels of NADPH (by
about 2-fold) in mutant cells (data not shown).
Decreased GSH-producing enzymes and increased activities of g-
glutamyl transpeptidase and glutathione-S-transferase in
mutant cells
Because increased glutathione levels could result from
increased GSH synthesis, we also studied GCL and glutathione
synthetase (GS) activities and analyzed the protein expression
levels of GCL catalytic subunit (GCLc). Unexpectedly, we observed
a significant decrease in GCL and GS activities in mutant cells,
compared to wild-type cells (Fig. 4A and B), suggesting decreased
GSH synthesis. We also observed a slight, although significant,
decrease in the protein levels of GCLc in mutant cells when
compared to wild-type cells (Fig. 4C), contributing to the
observed decrease in GCL activity (Fig. 4A). Since these results
did not explain the higher GSH levels observed in Fig. 2A and B,
we measured the activities of g–GT, an enzyme involved in GSH
degradation, and GST, which also participates in glutathione
metabolism. Our results demonstrate an increase in the activity
of g–GT in mutant cells when compared to wild-type cells
(Fig. 5A). Moreover, GST activity was also increased in total and
mitochondrial (although not significant) fractions obtained from
mutant cells, compared to wild-type cells (Fig. 5B and C), thus not
explaining the intracellular accumulation of GSH.
Decreased extracellular glutathione levels and Mrp1 mRNA levels on
expression of mutant huntingtin
In order to explain the higher levels of GSH in mutant cells, we
also evaluated the levels of glutathione by HPLC, which gives
information about total glutathione (GSH plus GSSG) levels.
Concordantly with data shown in Fig. 2, we observed a significant
increase in the intracellular total glutathione levels in mutant
cells (Fig. 6A). Because the activities of GSH metabolizing and
Fig. 2. Glutathione redox cycle on expression of full-length mutant huntingtin. Striatal cells were cultured for 48 h and then used to determine reduced (GSH) and oxidized
(GSSG) glutathione levels, and the activities of glutathione peroxidase (GPx) and glutathione reductase (GRed). Levels of total (A,C) and mitochondrial (B,D) GSH (A,B) and
GSSG (C,D) were significantly increased in mutant cells, when compared to wild-type cells (cellular GSH: 464600712140 RFU/mg protein; mitochondrial GSH:
5358673693 RFU/mg protein; cellular GSSG: 6380572350 RFU/mg protein; mitochondrial GSSG: 89657590 RFU/mg protein). GPx (E,F) and GRed (G,H) activities were
also examined in total (E,G) and mitochondrial (F,H) fractions. Data show significantly increased GPx and GRed activities in mutant cells, when compared to wild-type cells
(cellular GPx activity: 110.2717.1 mU/mg protein; mitochondrial GPx activity: 61.2718.3 mU/mg protein; cellular GRed activity: 36.173.2 mU/mg protein;
mitochondrial GRed activity: 21.472.7 mU/mg protein). Results are expressed as the mean7SEM of 3 to 4 independent experiments performed in triplicates. Statistical
analysis was performed by Student’s t test: nPo0.05; nnPo0.01 and nnnPo0.0001 when compared to wild-type cells.
M. Ribeiro et al. / Free Radical Biology and Medicine 53 (2012) 1857–18671862converting enzymes, g–GT and GST, were increased (Fig. 5), the
rise in GSH in mutant cells was still unexplained. Thus, we
analyzed whether an enhanced intracellular GSH pool resultedfrom cellular retention by evaluating the extracellular levels of
total glutathione in the culture medium of striatal cells main-
tained for 72 h in culture. Data in Fig. 6B show a slight, but
Fig. 3. NADPH-producing pentose phosphate pathway enzyme activities in
striatal mutant cells. HD mutant striatal cells from knock-in mice and wild-type
cells were used for analysis of glucose 6-phosphate dehydrogenase (G6PD),
6-phosphogluconate dehydrogenase (6PGD) activities, and G6PD mRNA levels.
G6PD (A) and 6PGD (B) activities were significantly increased in mutant cells,
when compared to wild-type cells, whereas G6PD mRNA levels (C) were
unchanged in mutant cells (G6PD activity in wild-type cells: 89.4711.2 mU/mg
protein; 6PGD activity in wild-type cells: 52.3710.1 mU/mg protein). The results
are expressed as the mean7SEM from 3 to 4 independent experiments performed
in triplicates. Statistical analysis was performed by Student’s t test: nPo0.05 and
nnnPo0.0001 when compared to wild-type cells.
Fig. 4. Activity and protein expression levels of enzymes involved in GSH synthesis in
mutant cells. GSH synthesis was determined through the analysis of (A) glutamate-
cysteine ligase (GCL) and (B) glutathione synthetase (GS) activities, and (C) catalytic
subunit of GCL (GCLc) protein levels, which were decreased in mutant versus wild-
type cells (GCL activity: 39817138.4 RFU/mg protein; GS activity: 57647223.7 RFU/
mg protein).The results are expressed as the mean7SEM from 3 to 6 independent
experiments performed in duplicates. Statistical analysis was performed by Student’s t
test: nPo0.05 or nnPo0.01 when compared to wild-type cells.
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glutathione (about 8% decrement of GSH plus GSSG levels present
in the culture medium, containing FBS) in the mutant striatal
cells, suggesting a deficit in its release.In order to explain the decrease in glutathione release we
determined the mRNA expression of Mrp1, a transport protein that
mediates cellular export of glutathione and glutathione conjugates
(e.g., [25]). Importantly, Mrp1 expression was largely and significantly
Fig. 5. Activities of gamma-glutamyltranspeptidase and glutathione-S-transferase
in HD knock-in striatal cells. Gamma-glutamyl transpeptidase (g–GT) (A) and
glutathione-S-transferase (GST) (B,C) were measured in total lysates (A,B) and
mitochondrial fractions (C) obtained from HD mutant and wild-type striatal cells.
g–GT and GST activities were increased in mutant cells when compared to wild-
type cells, although statistically significant results compared to wild-type cells
were observed in total fractions only (g–GT activity in wild-type cells: 372729.5
RFU/min/mg protein; cellular and mitochondrial GST activity in wild-type cells:
78.275.6 mmol/min/mg protein and 42.472.3 mmol/min/mg protein, respec-
tively). The results are expressed as the mean7SEM from 3 independent experi-
ments performed in duplicates. Statistical analysis was performed by Student’s t
test: nnnPo0.0001 when compared to wild-type cells.
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mHtt induces alterations in the glutathione dynamics due to altered
expression of Mrp1. This result was supported by a significant
increase in intracellular GSH levels in wild-type cells after Mrp1
inhibition with MK-571 (at 50 mM, for 24 h), whereas no changes
were detected in mutant cells (Fig. 6D). Additionally, we determined
the activity of Mrp1 based on the fluorescence of calcein. Mrp1 is
involved in the cellular export of calcein and therefore an increase in
calcein fluorescence may correlate with decreased Mrp1 activity [23].
In accordance with decreased expression of the protein, a significant
increase in intracellular calcein fluorescence was observed in mutant
cells, when compared to wild-type cells, indicating a decrease in
Mrp1 activity (Fig. 6E).Discussion
In this work we found evidence for oxidative stress in striatal
cells expressing FL-mHtt and thus more closely mimicking the
genetic expression of mHtt. Increased ROS occurs concomitantly
with enhanced intracellular glutathione levels and activity of the
glutathione redox cycle, despite the downward effects of mHtt on
the activity and expression of enzymes involved in GSH synthesis.
Importantly, decreased expression and activity of Mrp1 favor the
intracellular accumulation of glutathione.
Previous studies reported significantly higher ROS formation in
the striatum of R6/1 HD mice expressing exon 1 of mHtt, compared
to control mice [26]. In HD knock-in striatal cells, mitochondrial
dysfunction [27–29] may be related to increased formation of
superoxide (author’s unpublished data) and other cellular ROS, as
shown in this study. Moreover, in Wistar rats subjected to the
mitochondrial complex II inhibitor 3-nitropropionic acid (3-NP),
known to mimic some characteristics of HD, higher peroxide forma-
tion was detected when compared to untreated rats [30]. Although
HD knock-in striatal cells evidence increased ROS generation, they do
not exhibit massive cell death and large or visible mHtt aggregates
[17], thus mimicking initial HD cytopathological features. Never-
theless, these cells exhibit features of apoptosis, as demonstrated by
increased caspase-3 activation [14,31].
We further show that striatal cells expressing FL-mHtt present
higher levels of GSH compared to wild-type cells, although this is
not sufficient for preventing the rise in ROS. Indeed, treatment
with GSHee was effective in preventing ROS generation, revealing
that mutant cells are under a reversible state of oxidation. Also,
caspase-3 activation was ameliorated by treatment of mutant
striatal cells with GSHee, further suggesting that increased
intracellular accumulation of GSH is insufficient to rescue HD
cells from features of apoptotic cell death. Previously, treatment
of HD striatal cells with GSHee significantly prevented a 3-NP-
mediated decrease in mitochondrial membrane potential [32].
Although HD knock-in striatal cells showed increased levels of
glutathione, a decrease in GSH levels was previously described in
the cortex of HD patients [33]. In addition, decreased GSH levels
and higher lipid peroxidation were observed in the plasma of HD
symptomatic and asymptomatic individuals, compared to age-
and sex-matched controls, suggesting that oxidative stress may
occur before the onset of HD symptoms [34]. Conversely, the
levels of mitochondrial GSH were increased in the striatum and
cortex of R6/2 HD mice compared to wild-type animals, suggest-
ing a compensatory mechanism to counteract the increase in
mitochondrial ROS generation [16], which may also help to
explain our data. Despite this common result, the R6/2 mice
present a rapid progression of the disease and some phenotypes
not typically associated with HD [1], and thus considerably differ
from models expressing FL-mHtt.
Despite increased intracellular glutathione, here we demonstrate,
for the first time, a decrease in GCL and GS activities in striatal cell
lines expressing FL-mHtt, largely suggesting a decrease in GSH
synthesis. Additionally, GCLc protein (Fig. 4C) and mRNA (author’s
unpublished data) expression levels are significantly decreased in
mutant cells. In agreement, a decrease in GCL activity was previously
shown in the cortex and striatum of R6/2 HD, compared to wild-type
mice [16]. In the present work we show that this defect is also
observed following expression of FL-mHtt.
Along with increased cellular GSH in HD striatal cells, we
observed an increase in GSSG levels. In contrast, a significant
decrease in GSSG (by about 50%) was detected in the caudate
nucleus of HD patients [35]. We also observed an increase in GPx
activity. In accordance with these data, GPx1 transcription levels
were shown to be increased in three clones of striatal cells
expressing mHtt, compared to wild-type cells [14]. Nevertheless,
Fig. 6. Intracellular and extracellular glutathione and Mrp1 mRNA levels and activity on expression of mHtt. Striatal cells were incubated and the culture medium was
collected after 72 h in culture for analysis of extracellular glutathione. Cells were lysed and extra- and intracellular total glutathione (GSHþGSSG) levels were determined
by HPLC. (A) Intracellular glutathione levels were increased, whereas (B) extracellular glutathione levels decreased in mutant cells (intracellular and extracellular total
glutathione levels in wild-type cells: 24.8274.85 nmol/mg protein and 26.0674.96 nmol/mg protein, respectively). (C) mRNA levels of Mrp1 were also significantly
reduced in mutant cells, when compared to wild-type cells. (D) Intracellular GSH levels (48235479859 RFU/mg protein in wild-type cells) measured before and after
incubation with 50 mM MK-571; exposure to MK-571 increased GSH levels in wild-type cells only. (E) Mrp1 activity based on cellular export of fluorescent calcein
(7679072548 RFU/mg protein in wild-type cells). Results are expressed as the mean7SEM from 3 to 4 independent experiments performed in duplicates. Statistical
analysis was performed by Student’s t test: nPo0.05 or nnPo0.01 when compared to wild-type cells. For analysis of multiple groups (D) statistical analysis was performed
by two-way ANOVA followed by the Bonferroni post test: nnPo0.01 when compared to wild-type cells; ###Po0.0001 when compared to nontreated conditions.
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compared to control individuals [8], whereas in striatal tissue of R6/
1 HDmice GPx activity was not different [26], and GPx transcription
was unaltered in R6/2 HDmice [36], compared with wild-type mice.
Concordantly with our study, an increase in GRed activity was
found in erythrocytes from HD patients, compared to control
individuals [37] and increased GRed transcription was found in
the basal ganglia of R6/2 HD mice [36], suggesting a repository
mechanism of GSH levels. We also observed increased activity of
NADPH-producing enzymes of the pentose-phosphate pathway
(G6PD and 6PGD), which is relevant since NADPH is an important
cofactor of GRed. Indeed, NADPH levels were significantly
increased in striatal mutant cells (data not shown), which may
explain the higher activity of GRed. Changes in G6PD activity in
HD models are controversial. G6PD activity was found to be
increased in erythrocytes from HD patients [37], but decreased
in the striatum from R6/2 mice [16]. Moreover, hexokinase, a
prime enzyme in glycolysis and in the pentose-phosphate path-
way upstream G6PD, was found to be actively increased in thebrain of 3-NP-treated and in the HD transgenic N171-82Q mouse
models [38].
Despite decreased GSH synthesis in HD striatal cells, we show
that glutathione was accumulated intracellularly; this was not
explained by alterations in GST or g–GT (both involved in glu-
tathione metabolism), since their activities were increased in
mutant cells. Conversely, increased intracellular glutathione could
be due to decreased release of the endogenous antioxidant to the
extracellular milieu by Mrp1, which mediates the export of GSH
and GSH conjugates in an ATP-dependent manner [25,39], thus
also requiring a functional metabolic status of the cells. Mrp1 is a
190-kDa protein involved in cellular xenobiotics metabolite detox-
ification, namely carcinogens, pesticides, herbicides, or metalloids.
Mrp1 is highly overexpressed in many drug-resistant tumor cell
lines and expressed at moderate levels in most normal tissues. In
the brain it is part of the drug permeability barrier between the
blood and the cerebrospinal fluid [40]. No data describing the Mrp1
involvement in HD have been reported until now. Here, we show
that mRNA levels of Mrp1 are decreased in mutant HD striatal cells,
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tion regulation [41]. Indeed, mHtt interacts with and sequesters
CBP (CREB-binding protein, a coactivator of transcription that
forms a complex with cAMP response-element (CRE) binding
protein (CREB) to initiate gene transcription [42]) within protein
aggregates [43], and decreases the activity of PGC-1a (peroxisome
proliferator-activated receptor-g coactivator 1a), a transcriptional
regulator of mitochondrial biogenesis and antioxidant enzymes
(e.g., [44]). By directly interacting with transcription factors or
coactivators, mHtt represses normal cellular transcription activity
and thus may modify normal Mrp1 expression.
In astrocytes, Mrp1 was previously reported to mediate 60% of
the GSH export and to be exclusively responsible for GSSG export
[45]. Moreover, due to its role in the transport of glutathione-S-
conjugates and GSSG into the extracellular space, proteins of the
Mrp family may play an important function in defense mechanisms
against oxidative stress [46]. Concordantly with the decreased
expression of Mrp1, we observed that Mrp1 activity is affected in
mutant cells. Furthermore, we observed a significant increase in
intracellular GSH levels in wild-type cells, but not in mutant striatal
cells after inhibition of Mrp1 with MK-571, largely evidencing the
dysfunction in this transport protein in HD cells. No changes of
intracellular GSH levels were observed in mutant cells, reinforcing
the hypothesis of decreased Mrp1 function on expression of FL-
mHtt. In this perspective, mHtt or its fragments may also directly
affect the activity of Mrp1, as depicted in the graphical abstract,
although more studies will be required to test this hypothesis.
In summary, our results show that striatal cells expressing
FL-mHtt exhibit raised antioxidant defense profiles through
increased activity of the glutathione redox cycle and related meta-
bolic enzymes, namely GST and g–GT, despite decreased GSH
synthesis. Interestingly, our work gives evidence that decreased
expression and activity of Mrp1 result in decreased release of
glutathione, leading to its intracellular accumulation. Although this
is apparently insufficient to prevent oxidative stress and apoptotic
features, it may result from an attempt of HD striatal cells that do
not exhibit massive cell death or visible mHtt aggregates to
counterbalance initial generation of ROS evoked by FL-mHtt.Acknowledgments
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